Semantic dementia (SD) is a form of frontotemporal dementia (FTD), characterized by the progressive, amodal and profound loss of semantic knowledge (combination of visual associative agnosia, anomia, ...
Comprehensive, easy-to-understand information about this condition
How we create this content →Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Connect with organizations supporting the semantic dementia community
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 8, 2026
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
1 peer-reviewed source from PubMed
AI-Generated Content: This summary was generated using AI. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 3 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning semantic dementia
Updated Feb 10, 2026
A recent NIH-funded study suggests that cognitive speed training can delay the diagnosis of dementia by engaging unconscious thinking processes. This innovative approach may offer new strategies for long-term cognitive health.
Eli Lilly has decided to discontinue three therapies, including a gene therapy for dementia acquired through its $1.04 billion purchase of Prevail Therapeutics. This move aligns with Lilly's strategy to focus on its GLP-1 pipeline.
A new NIH-funded study establishes a clear link between severe chronic traumatic encephalopathy (CTE) and increased dementia risk. This research could influence future therapeutic strategies and patient management for individuals with a history of head trauma.